SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech binary events
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: dalroi who started this subject10/7/2003 5:35:16 PM
From: nigel bates  Read Replies (1) of 295
 
NPSP, March(?) '04

Message 19379805
NPS announced that it has completed dosing of all patients that participated in its pivotal, 18-month Phase III trial for PREOS, which is recombinantly produced, full-length human parathyroid hormone, (PTH). The trial, known as the TOP (Treatment of Osteoporosis with PTH) study, was designed to test the ability of PREOS to reduce fracture rates in postmenopausal women with osteoporosis. NPS expects to report results of the TOP study late in the first quarter of 2004....
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News